Lexology September 26, 2024
On September 11-12, we had the pleasure of attending the LSX World Congress USA in Boston, where leaders discussed the challenges and opportunities of M&A and partnerships in the pharmaceutical sector.
I was honored to moderate a panel session on ‘Pharma Fusion: Spearheading Growth Through M&A and Partnering in 2024’. As a leading firm in the life sciences and healthcare sector, A&O Shearman is committed to supporting high-growth companies through their early- and mid-term funding stages to IPO, as well as on a range of M&A, licensing, collaborations, and high-stakes patent litigation work. We work across the industry, including with biotech, pharma, consumer healthcare, data and medtech companies.
Dealmaking is always happening While there are fewer high-publicity megadeals propelling pharma...
Today's Sponsors
Today's Sponsor